Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

834
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
834
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

764
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
764
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

74
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·2001
Same author

Introduction: evidence to practice in acute coronary syndromes.

The American journal of cardiology·2001
Same author

Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.

Journal of the American College of Cardiology·2001
Same author

Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.

Circulation·2001
Same author

Statistical approaches and policies for the operations of Data and Safety Monitoring Committees.

American heart journal·2001
Same author

Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.

The Journal of invasive cardiology·2001

Related Experiment Video

Updated: May 7, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

25.1K

The rationale for thrombolytic therapy.

R M Califf1

  • 1Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

European Heart Journal
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Understanding acute myocardial infarction (heart attack) reveals plaque rupture causes vessel blockage. Early reperfusion therapy improves survival but carries risks like bleeding, requiring careful benefit-risk assessment.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.2K

Related Experiment Videos

Last Updated: May 7, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

25.1K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.2K

Area of Science:

  • Cardiovascular Medicine
  • Pathophysiology of Atherosclerosis
  • Thrombolytic Therapy Research

Background:

  • Acute myocardial infarction (heart attack) pathophysiology involves atherosclerotic plaque rupture.
  • Plaque rupture exposes subendothelial tissue, triggering thrombosis and vessel obstruction.
  • Myocardial cell death progresses from subendocardium to epicardium.

Purpose of the Study:

  • To review the understanding of acute myocardial infarction pathophysiology.
  • To evaluate the efficacy and risks of reperfusion therapies.
  • To guide future evaluations of novel thrombolytic regimens.

Main Methods:

  • Review of pathophysiological mechanisms of acute myocardial infarction.
  • Analysis of data from large thrombolytic trials.
  • Assessment of determinants of final infarct area (reperfusion time, collateral flow).

Main Results:

  • Thrombolytic therapy provides a survival benefit compared to controls.
  • Earlier, more complete reperfusion is linked to lower mortality.
  • Potent thrombolytic therapies may increase complication rates (e.g., intracranial hemorrhage, reocclusion).

Conclusions:

  • Therapeutic strategies focus on early and sustained reperfusion of the infarct-related artery.
  • While beneficial, thrombolytic therapies require careful consideration of associated risks.
  • Future research should weigh the benefits against risks of newer thrombolytic agents.